congenital heart disease with pulmonary hypertension; surgery or medical treatment?

Authors

احمد میردامادی

استادیار، گروه قلب، دانشکده ی پزشکی، دانشگاه آزاد اسلامی، واحد نجف آباد، اصفهان، ایران سمیرا اشرفی

کارشناس ارشد، آزمایشگاه تحقیقاتی، دانشگاه اصفهان، اصفهان، ایران

abstract

pulmonary arterial hypertension (pha) is a frequent complication of congenital heart disease (chd), most commonly in systemic-to-pulmonary shunt lesions. in patients with an uncorrected left-to right shunt, pah will end up to eisenmenger’s syndrome, which is contraindication of surgery. what about patients with moderate to severe pah, who do not have criteria of eisenmenger’s syndrome; immediate cardiac repair is preferred or medical treatment? heart catheterization and evaluation of pulmonary artery reactivity test or lung biopsy might be helpful to find presence of eisenmenger’s syndrome. although these guidelines are not always helpful or possible; look at the following article will show how important this subject is. 192 patient with chd and pah were evaluated in 4 groups, eisenmenger’s syndrome (90 patients), left-to-right shunt with pah (48 patients), pah with small defect (10 patients) and pah after defect correction (44 patients). 1-, 5-, 10-, and 20-year survivals were estimated for each group. findings showed that patients with history of surgery in presence of pah had worst outcome; and patients with eisenmenger’s syndrome and those with pah-associated left-to-right shunt had best prognosis. one of the reasons of this result is presence of a cardiac defect which allows a pulmonary-to-systemic shunt which can maintain the cardiac output in the end stage of disease. finally, we present a young girl with history of chd with pah. she had been operated several years ago. when admitted, she was in a bad condition, with functional class of iv. echocardiography showed severe pah. treatment of pah started with specific target pah drugs immediately, but these treatments were too late and patient expired in the hospital. finally, we would like to pose the question ”would not it be better if the patient had not undergone the surgery in the first place?”.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Evaluation of QRS, QTc, and JTc intervals in Congenital Heart Disease with Pulmonary Hypertension

Background Pulmonary hypertension (PH) in congenital heart disease affects the patient’s prognosis. Prolonged QRS and QTc intervals in ECG may intensify life-threatening dysrhythmia in patients. We aimed to investigate the correlation between QRS, QTc, and JTc intervals prolongation in ECG with PH in Congenital Heart Disease (CHD) patients. Mate...

full text

[Pulmonary hypertension associated with congenital heart disease].

INTRODUCTION Congenital heart diseases are among the most common congenital malformations at birth with an incidence of 8/1,000 live births. These defects are characterized by a heterogeneous group of abnormal defects and connections between the cardiac chambers and vessels with different haemodynamic consequences and hence, varying need for follow-up and interventions. The most common forms ar...

full text

Congenital heart disease and pulmonary hypertension.

Many patients with congenital heart disease and systemic-to-pulmonary shunts develop pulmonary arterial hypertension (PAH), particularly if the cardiac defect is left unrepaired. A persistent increase in pulmonary blood flow may lead to obstructive arteriopathy and increased pulmonary vascular resistance, a condition that can lead to reversal of shunt and cyanosis (Eisenmenger syndrome). Cardia...

full text

Congenital Heart Disease and Pulmonary Hypertension

Pulmonary hypertension is common in patients with congenital heart disease, even in those patients with previously repaired lesions, and can lead to considerable symptoms, including exertional dyspnea. Pulmonary hypertension in these patients can be caused by pulmonary arterial or pulmonary venous causes and requires heart catheterization for accurate diagnosis. Some patients may be able to be ...

full text

Riociguat for pulmonary arterial hypertension associated with congenital heart disease

OBJECTIVE The Pulmonary Arterial hyperTENsion sGC-stimulator Trial-1 (PATENT-1) was a randomised, double-blind, placebo-controlled phase III trial evaluating riociguat in patients with pulmonary arterial hypertension (PAH). PATENT-2 was an open-label long-term extension to PATENT-1. Here, we explore the efficacy and safety of riociguat in the subgroup of patients with persistent/recurrent PAH a...

full text

Management of pulmonary arterial hypertension associated with congenital heart disease.

Congenital heart diseases are the most common congenital malformations and account for about eight cases per 1000 births and are often associated with pulmonary arterial hypertension. Increased shear stress and the excess flow through the pulmonary vascular bed due to a systemic-to-pulmonary shunt lead to the development of pulmonary vascular disease and an increase in pulmonary vascular resist...

full text

My Resources

Save resource for easier access later


Journal title:
مجله دانشکده پزشکی اصفهان

جلد ۳۲، شماره ۳۰۷، صفحات ۱۸۳۸-۱۸۴۳

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023